Peptide Therapy Bloodwork: What to Test for Safety and Results

Search "peptide testing" and two completely different needs collide. Sorting them out first saves you from ordering the wrong thing:

Testing your body's response (this guide). A blood test measures what a peptide is doing to your physiology — your IGF-1, hormones, blood sugar, liver and kidney function, inflammation. This is medical lab work, ordered online and drawn at Quest or Labcorp, and it's what tells you whether a protocol is safe for you and whether it's working. That's what TestWell provides.

Testing the vial's contents. Verifying the identity, purity, or concentration of the peptide in a vial is analytical chemistry (mass spectrometry, HPLC) done by a substance-testing lab. A human medical lab cannot do it, and no blood test can tell you what was in the vial. If that's what you need, you're looking for a chemical assay service, not us.

The rest of this guide is about the first case — using your own bloodwork to make peptide therapy safer and more measurable.

Peptides are signaling molecules — they tell your body to do something: release growth hormone, slow gastric emptying, modulate repair and inflammation. Because they act upstream, their effects ripple through exactly the systems a comprehensive blood panel measures, and many of those effects are silent until they're advanced:

• Growth-hormone-releasing peptides (CJC-1295, ipamorelin, sermorelin, MK-677/ibutamoren) raise IGF-1 and can nudge fasting glucose and insulin. You won't feel a rising IGF-1 or a creeping insulin resistance — but both show up in blood.
• GLP-1 receptor agonists (semaglutide, tirzepatide) can transiently raise liver enzymes, rarely stress the kidneys during dehydration, and — because they work by suppressing appetite — quietly drain the nutrients you're no longer eating enough of.
• Repair and recovery peptides (BPC-157, TB-500/thymosin) are taken precisely when people don't want to interrupt training or healing — the moment you'd most want objective evidence that organ and inflammation markers are holding steady.

The through-line: peptide effects are measurable long before they're noticeable. Bloodwork converts "I think it's working / I feel fine" into a trend line you can actually act on.

Clinicians who monitor peptide therapy well tend to follow the same cadence, and it's simple enough to run yourself:

• Baseline (before you start). The single most valuable draw. Without a "before" picture, a later result has nothing to be compared against — a normal-looking IGF-1 means little if you don't know where you started. Baseline also catches pre-existing issues that a peptide could worsen.
• Early follow-up (4-6 weeks in). Confirms the protocol is doing what it should (IGF-1 moving on a GH peptide; glucose and lipids improving on a GLP-1) and that nothing is drifting the wrong way (liver enzymes, insulin) while it's still easy to adjust.
• Quarterly thereafter. Ongoing therapy calls for ongoing monitoring. Every ~90 days keeps the trend current and catches slow shifts. This is also why a recurring lab plan fits peptide users so naturally — the retest is the whole point.

Timing detail that matters: on injectable peptides, draw at trough — right before your next dose — for a consistent, comparable baseline. For weekly GLP-1 injections, draw at the same point in your weekly cycle each time. Most of these panels also require a 10-12 hour fast and a morning draw for accurate cortisol and hormone readings.

Different peptides stress different systems. The markers that matter most:

GH-releasing peptides (CJC-1295, ipamorelin, sermorelin, MK-677). IGF-1 is the primary efficacy marker — it's the stable downstream signal of growth-hormone activity, and if it isn't moving, the protocol isn't doing much. Pair it with fasting glucose, insulin, and HbA1c, because GH-axis stimulation can raise blood sugar, plus a full thyroid panel and IGF-1's metabolic neighbors.

GLP-1 medications (semaglutide, tirzepatide). Liver and kidney function via CMP, glucose control via A1c and insulin, lipids, thyroid, and the nutrition markers that fall on an appetite-suppressed diet — B12, ferritin, vitamin D. Our GLP-1 lab monitoring guide covers this in depth.

Repair peptides (BPC-157, TB-500). There's no single "BPC-157 marker," so monitoring is about safety and baseline stability: organ function (CMP), blood health (CBC), and inflammation (hs-CRP). Our BPC-157 bloodwork guide explains what you can and can't learn from labs here.

Rather than assemble these piecemeal, the Peptide Therapy Monitoring Panel bundles all 53 biomarkers most peptide users track — including SHBG for accurate free-testosterone interpretation — into one draw at roughly half the à la carte cost. For the rechecks after that baseline, the smaller Peptide Essentials Panel repeats just the four tests that move on a cycle — IGF-1, CMP, lipid panel and CBC with differential.

Being straight about this builds more trust than glossing over it:

Many research peptides (BPC-157, TB-500, and most GH secretagogues) are not FDA-approved for general human use and are sold "for research purposes only." GLP-1 medications like semaglutide and tirzepatide are FDA-approved but are prescription drugs meant to be taken under medical supervision. TestWell does not sell, source, prescribe, or dose peptides, and nothing here is a recommendation to start any peptide.

What bloodwork offers is harm reduction and measurement: if you or your clinician have decided on a protocol, objective labs before and during are how you catch problems early and confirm benefit. That's a genuinely valuable, defensible use of testing — the same principle behind monitoring any therapy by its effects on the body.

Every TestWell order is reviewed by a licensed physician, drawn at CLIA-certified labs, and returned with a plain-language summary in your portal. If a result is abnormal, that's your cue to involve a clinician — bloodwork informs the conversation, it doesn't replace it.